Adding a targeted agent to chemotherapy failed to improve survival as initial therapy for metastatic urothelial carcinoma, a randomized trial showed. Median overall survival (OS) was about 14 months ...
MedPage Today on MSN
Regimen Improves PFS in Highly Mutated Metastatic Colorectal Cancer
Accrual in this trial was suspended in March 2025 as a result of findings from the Checkmate 8HW trial, which showed that the ...
In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab ...
Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal ...
The FDA issued a third complete response letter for ONS-5010/Lytenava, requesting confirmatory efficacy evidence for wet AMD treatment. Lytenava is an ophthalmic bevacizumab formulation, potentially ...
National Institute for Health and Care Excellence (NICE) has recommended Lonsurf (trifluridine–tipiracil, Servier Laboratories) plus bevacizumab in final draft guidance for treating metastatic ...
Zacks Investment Research on MSN
OTLK stock crashes 67% in a week: Here's what you need to know
Shares of Outlook Therapeutics OTLK have tumbled 66.5% in a week. The massive crash was observed after the FDA issued a third ...
Abstracts presented at the 2022 American Society of Clinical Oncology Annual Meeting show bevacizumab-awwb to be safe and effective for patients with metastatic colorectal cancer (mCRC) with high ...
ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback